Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Munro

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
BMC Pharmacology|May 31, 2012
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicityThomas A Munro, Loren M Berry, Ashlee Van't Veer, et al.
Bioorganic & Medicinal Chemistry|November 6, 2007
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethersThomas A Munro, Katharine K Duncan, Wei Xu, et al.
Beilstein Journal of Organic Chemistry|January 11, 2007
8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptorThomas A Munro, Katharine K Duncan, Richard J Staples, et al.
Bioorganic & Medicinal Chemistry|January 17, 2009
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptorCécile Béguin, Katharine K Duncan, Thomas A Munro, et al.
Psychopharmacology|December 9, 2010
Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trialJohn E Mendelson, Jeremy R Coyle, Juan Carlos Lopez, et al.
Plos One|August 27, 2013
Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transportersThomas A Munro, Xi-Ping Huang, Carmela Inglese, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2007
N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacyCécile Béguin, David N Potter, Jennifer A Dinieri, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
BMC Pharmacology|May 31, 2012
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicityThomas A Munro, Loren M Berry, Ashlee Van't Veer, et al.
Bioorganic & Medicinal Chemistry|November 6, 2007
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethersThomas A Munro, Katharine K Duncan, Wei Xu, et al.
Beilstein Journal of Organic Chemistry|January 11, 2007
8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptorThomas A Munro, Katharine K Duncan, Richard J Staples, et al.
Bioorganic & Medicinal Chemistry|January 17, 2009
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptorCécile Béguin, Katharine K Duncan, Thomas A Munro, et al.
Psychopharmacology|December 9, 2010
Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trialJohn E Mendelson, Jeremy R Coyle, Juan Carlos Lopez, et al.
Plos One|August 27, 2013
Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transportersThomas A Munro, Xi-Ping Huang, Carmela Inglese, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2007
N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacyCécile Béguin, David N Potter, Jennifer A Dinieri, et al.
Pageof 2